Boreo’s subsidiary Muottikolmio acquires Lamox Oy
BOREO PLC Investor news 3 March 2023 at 10:00 EET
Boreo’s subsidiary Muottikolmio acquires Lamox Oy
Boreo’s subsidiary Muottikolmio Oy has on March 3, 2023, signed and closed a share and purchase agreement to acquire entire share capital of Lamox Oy, from Malum Oy.
The add-on acquisition supports Muottikolmio’s growth ambitions, enables wider product offering and improves the company’s position within the renovation construction market. Lamox is Muottikolmio’s long-term supplier of patented Termotuote products.
Founded in 2013, Lamox is a manufacturer of patented Termotuote products which are used in hidden socle repairs. During its years in business, Termotuote has gained a strong position among building companies and constructors. Lamox’s operations are located in Alajärvi, Finland. In FY 2022, Lamox had revenues of c. EUR 0,6 million and an EBITDA of c. EUR 0,1 million.
Lamox will be reported under Boreo’s Technical Trade Business Area.
Vantaa, 3 March 2023
NASDAQ Helsinki Ltd
tel +358 44 341 8514
tel +358 40 556 3546
Lamox Oy – Key financials1
|Total assets, EURm||0,4||0,4||0,3|
|Net debt, EURm||(0,2)||(0,2)||(0,2)|
 Illustrative key financials are based on Finnish Accounting Standards (FAS), financial year ending 30.4.
Boreo in brief:
Boreo is a company listed on Nasdaq Helsinki that creates value by owning, acquiring and developing small and medium sized companies in Northern Europe. Boreo's business operations are organized into three business areas: Electronics, Technical Trade and Heavy Machines.
Boreo’s main objective is to create shareholder value in the long-term. It aims to achieve this with an acquisition-driven strategy, creating optimal conditions for its businesses to increase sales and improve profitability, and by being a best-in-class home for its companies and personnel.
The Group's net sales in 2022 were EUR 160.4 million and it employs over 300 people in seven countries. The company’s headquarter is in Vantaa.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Kvika banki hf.: Annual General Meeting 30 March 2023 - Candidacy to the Board and amended proposals of the BoD27.3.2023 15:48:10 CEST | Press release
The deadline for candidacy to the Board expired on 25 March 2022. The following candidates have submitted their application for the Board of Directors at the AGM, to be held on 30 March, at 4:00 pm at Grand Hotel, Háteigur, Sigtún 28, 150 Reykjavík, also accessible online through Lumi AGM: In candidacy for the Board of Directors: Sigurður HannessonGuðmundur ÞórðarsonGuðjón ReynissonHelga Kristín AuðunsdóttirIngunn Svala Leifsdóttir In candidacy as alternate members: Helga Jóhanna OddsdóttirSigurgeir Guðlaugsson It is the assessment of the Board that all candidacies are valid in accordance with Act No. 2/1995 respecting Public Limited Companies. According to the company’s articles of association the Board of Directors shall consist of five members and two alternate members. As no further candidates have applied for the Board of Directors or as alternate members, the candidates are self-elected. Attention is drawn to an amendment proposal from Gildi Pension Fund regarding the wording of
07/2023 Green Hydrogen Systems - Financial calendar 2023 (updated)27.3.2023 15:45:00 CEST | Press release
Company announcement 07/2023 Green Hydrogen Systems updatesfinancial calendar for 2023 Kolding, Denmark, 27 March 2023 – Green Hydrogen Systems A/S hereby updates its financial calendar for 2023: Q1 2023 Trading Statement: 17 April 2023 (updated) Annual General Meeting: 18 April 2023 Q2 2023 Interim Report: 22 August 2023 Q3 2023 Trading Statement: 1 November 2023 For more info please contact: Investors: Jens Holm Binger, Head of Investor Relations, +45 6065 6525, email@example.com Media: Jesper Buhl, Head of Public Affairs and Media Relations, +45 5351 5295, firstname.lastname@example.org Green Hydrogen Systems in brief Green Hydrogen Systems is a clean technology company and a leading provider of standardised and modular electrolysers for the production of green hydrogen solely based on renewable energy. With its wide range of possible applications, green hydrogen plays a key role in the ongoing fundamental shift in our energy systems towards a net-zero emission society in 2050. As a result
NATALEE (TRIO033) Phase III trial demonstrates ribociclib significantly reduces the risk of recurrence for patients with early breast cancer, at interim analysis27.3.2023 15:28:42 CEST | Press release
EDMONTON, Alberta, March 27, 2023 (GLOBE NEWSWIRE) -- Translational Research In Oncology (TRIO) today announced positive topline results from NATALEE (TRIO033), a Novartis sponsored Phase III trial of ribociclib plus endocrine therapy (ET) as adjuvant treatment for patients with stages II and III early breast cancer (EBC) at risk of disease recurrence. NATALEE (TRIO033) met its primary endpoint at a pre-planned interim analysis, achieving a statistically significant improvement in invasive disease-free survival (iDFS) in women and men with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) EBC, when compared to ET alone. “At TRIO, we always strive to improve the lives of cancer patients by conducting clinical trials that might make a fundamental difference in outcomes. We are very proud of our collaboration with Novartis in the conduct of the NATALEE (TRIO033) trial. The results announced today are a significant step forward towards reducing the ris
Sbanken ASA: Tap Issue ISIN NO001108758727.3.2023 15:19:31 CEST | Press release
Tap Issue Sbanken ASA 21/25 FRN C, ISIN NO0011087587 amount NOK 800.000.000,-. New outstanding amount NOK 3.500.000.000,- This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Sbanken ASA: Utvidelse av ISIN NO001108758727.3.2023 15:19:31 CEST | Pressemelding
Utvidelse av Sbanken ASA 21/25 FRN C, ISIN NO0011087587 beløp NOK 800.000.000,- Nytt utestående volum NOK 3.500.000.000,- Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12